Immunocore Holdings plc - ADR

+0.33 (+0.87%)
Products, Regulatory

Immunocore Presents New Data From Its Phase 2 Clinical Trial Of Tebentafusp At The ESMO Congress 2021

Published: 09/20/2021 11:59 GMT
Immunocore Holdings plc - ADR (IMCR) - Immunocore Presents Data at the European Society for Medical Oncology (esmo) Congress 2021 Demonstrating a Reduction in Circulating Tumor Dna (ctdna) While on Tebentafusp is Associated With Overall Survival in the Phase 2 Clinical Trial.
Immunocore Holdings Plc - Linear Correlation Between Magnitude of Ctdna Reduction on Tebentafusp and Improved Overall Survival.
Immunocore Holdings Plc - 70% of Evaluable Patients Had Any Ctdna Reduction and 14% Had Ctdna Clearance.